Research progress of PCSK9 affecting cardiovascular diseases through non-low-density lipoprotein cholestero-l pathway
-
摘要: 前蛋白转化酶枯草杆菌蛋白酶/kexin 9(PCSK9)是前蛋白转化酶家族的第9个成员，是一组丝氨酸蛋白酶，主要由肝脏分泌并释放到血液，通过降解低密度脂蛋白受体(low-density lipoprotein receptor，LDLR)来升高低密度脂蛋白胆固醇(low-density lipoprotein cholesterol，LDL-C)，从而促进动脉粥样斑块的形成。PCSK9抑制剂的出现为血脂异常的治疗开辟了新途径。近年来越来越多的研究表明，PCSK9不仅调节肝脏的脂质代谢，同时还参与肝外器官的生理病理过程，影响多种心血管疾病。本文就PCSK9与心血管疾病的最新进展进行综述。
-
关键词:
- 前蛋白转化酶枯草杆菌蛋白酶/kexin 9 /
- 心血管疾病 /
- 低密度脂蛋白胆固醇 /
- PCSK9抑制剂 /
- 非低密度脂蛋白胆固醇
Abstract: PCSK9, the ninth member of the proprotein convertase family, is a group of serine proteases secreted primarily by the liver and released into the bloodstream. There, it degrades the low-density lipoprotein receptor(LDLR) thus increasing low-density lipoprotein cholesterol(LDL-C) and promoting the formation of atherosclerotic plaque. The emergence of PCSK9 inhibitors has opened up a new way for the treatment of dyslipidemia. In recent years, more and more studies have shown that PCSK9 not only regulates lipid metabolism in the liver, but also participates in the physiological and pathological processes of extrahepatic organs, affecting a variety of cardiovascular diseases. This article reviews the latest progress of PCSK9 and cardiovascular diseases. -
-
[1] Malo J, Parajuli A, Walker SW. PCSK9: from molecular biology to clinical applications[J]. Ann Clin Biochem, 2020, 57(1): 7-25. doi: 10.1177/0004563219864379
[2] Ben-Naim L, Khalaila I, Papo N. Modifying pH-sensitive PCSK9/LDLR interactions as a strategy to enhance hepatic cell uptake of low-density lipoprotein cholesterol(LDL-C)[J]. Protein Eng Des Sel, 2022, 35.
[3] Barale C, Melchionda E, Morotti A, et al. PCSK9 Biology and Its Role in Atherothrombosis[J]. Int J Mol Sci, 2021, 22(11).
[4] Da Dalt L, Castiglioni L, Baragetti A, et al. PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction[J]. Eur Heart J, 2021, 42(32): 3078-3090. doi: 10.1093/eurheartj/ehab431
[5] Talasaz AH, Ho AJ, Bhatty F, et al. Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD[J]. Pharmacotherapy, 2021, 41(12): 1009-1023. doi: 10.1002/phar.2635
[6] Giugliano RP, Mach F, Zavitz K, et al. Cognitive Function in a Randomized Trial of Evolocumab[J]. N Engl J Med, 2017, 377(7): 633-643. doi: 10.1056/NEJMoa1701131
[7] Taskinen MR, Björnson E, Kahri J, et al. Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100-and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes[J]. Arterioscler Thromb Vasc Biol, 2021, 41(2): 962-975. doi: 10.1161/ATVBAHA.120.315446
[8] Sharotri V, Collier DM, Olson DR, et al. Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9(PCSK9)[J]. J Biol Chem, 2012, 287(23): 19266-19274. doi: 10.1074/jbc.M112.363382
[9] Blom DJ, Djedjos CS, Monsalvo ML, et al. Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study[J]. Circ Res, 2015, 117(8): 731-741. doi: 10.1161/CIRCRESAHA.115.307071
[10] Ghosh M, Galman C, Rudling M, et al. Erratum: Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol[J]. J Lipid Res, 2018, 59(11): 2253. doi: 10.1194/jlr.M055780ERR
[11] 冯若男, 周华. PCSK9与动脉粥样硬化性心血管疾病的研究进展[J]. 中国动脉硬化杂志, 2020, 28(12): 5. https://www.cnki.com.cn/Article/CJFDTOTAL-KDYZ202012016.htm
[12] Ding Z, Pothineni N, Goel A, et al. Corrigendum to: PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1[J]. Cardiovasc Res, 2022, 118(8): 2031. doi: 10.1093/cvr/cvab352
[13] Badimon L, Luquero A, Crespo J, et al. PCSK9 and LRP5 in macrophage lipid internalization and inflammation[J]. Cardiovasc Res, 2021, 117(9): 2054-2068. doi: 10.1093/cvr/cvaa254
[14] Yan L, Jia Q, Cao H, et al. Fisetin ameliorates atherosclerosis by regulating PCSK9 and LOX-1 in apoE-/-mice[J]. Exp Ther Med, 2021, 21(1): 25.
[15] Punch E, Klein J, Diaba-Nuhoho P, et al. Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis[J]. J Am Heart Assoc, 2022, 11(3): e023328. doi: 10.1161/JAHA.121.023328
[16] Tang ZH, Peng J, Ren Z, et al. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway[J]. Atherosclerosis, 2017, 262: 113-122. doi: 10.1016/j.atherosclerosis.2017.04.023
[17] Guo Y, Yan B, Tai S, et al. PCSK9: Associated with cardiac diseases and their risk factors?[J]. Arch Biochem Biophys, 2021, 704: 108717. doi: 10.1016/j.abb.2020.108717
[18] Barale C, Melchionda E, Morotti A, et al. PCSK9 Biology and Its Role in Atherothrombosis[J]. Int J Mol Sci, 2021, 22(11): 5880. doi: 10.3390/ijms22115880
[19] Gao Y, Zhang HB, Hou LL, Wang SM. Predictive value of plasma PCSK9 levels in acute myocardial infarction patients without reperfusion therapy for recurrence of cardiovascular events within 1 year[J]. Zhonghua Yi Xue Za Zhi, 2019, 99(35): 2750-2755.
[20] Luquero A, Badimon L, Borrell-Pages M. PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation[J]. Front Cardiovasc Med, 2021, 8: 639727. doi: 10.3389/fcvm.2021.639727
[21] Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome[J]. N Engl J Med, 2018, 379(22): 2097-2107. doi: 10.1056/NEJMoa1801174
[22] Lopes RD, de Barros E Silva P, de Andrade Jesuíno I, et al. Timing of Loading Dose of Atorvastatin in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the SECURE-PCI Randomized Clinical Trial[J]. JAMA Cardiol, 2018, 3(11): 1113-1118. doi: 10.1001/jamacardio.2018.3408
[23] Räber L, Ueki Y, Otsuka T, et al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial[J]. JAMA, 2022, 327(18): 1771-1781. doi: 10.1001/jama.2022.5218
[24] Lewis BS. Atrial fibrillation and stroke prevention[J]. Eur Heart J Cardiovasc Pharmacother, 2021, 7(FI1): f1-f2. doi: 10.1093/ehjcvp/pvab023
[25] Pastori D, Ettorre E, Carnevale R, et al. Atherosclerosis in Atrial Fibrillation Study, Interaction between serum endotoxemia and proprotein convertase subtilisin/kexin 9(PCSK9) in patients with atrial fibrillation: A post-hoc analysis from the ATHERO-AF cohort[J]. Atherosclerosis, 2019, 289: 195-200. doi: 10.1016/j.atherosclerosis.2019.07.002
[26] Kwakernaak AJ, Lambert G, Muller Kobold AC, et al. Adiposity blunts the positive relationship of thyrotropin with proprotein convertase subtilisin-kexin type 9 levels in euthyroid subjects[J]. Thyroid, 2013, 23(2): 166-172. doi: 10.1089/thy.2012.0434
[27] Lurie A, Wang J, Hinnegan KJ, et al. Prevalence of Left Atrial Thrombus in Anticoagulated Patients With Atrial Fibrillation[J]. J Am Coll Cardiol, 2021, 77(23): 2875-2886. doi: 10.1016/j.jacc.2021.04.036
[28] Cammisotto V, Pastori D, Nocella C, et al. PCSK9 Regulates Nox2-Mediated Platelet Activation via CD36 Receptor in Patients with Atrial Fibrillation[J]. Antioxidants(Basel), 2020, 9(4): 296.
[29] Paciullo F, Petito E, Falcinelli E, et al. Pleiotropic effects of PCSK9-inhibition on hemostasis: Anti-PCSK9 reduce FVⅢ levels by enhancing LRP1 expression[J]. Thromb Res, 2022, 213: 170-172. doi: 10.1016/j.thromres.2022.03.021
[30] Bovenschen N, Herz J, Grimbergen JM, et al. Elevated plasma factor Ⅷ in a mouse model of low-density lipoprotein receptor-related protein deficiency[J]. Blood, 2003, 101(10): 3933-3939. doi: 10.1182/blood-2002-07-2081
[31] Pastori D, Nocella C, Farcomeni A, et al. Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation[J]. J Am Coll Cardiol, 2017, 70(12): 1455-1462. doi: 10.1016/j.jacc.2017.07.743
[32] Yang S, Shen W, Zhang HZ, et al. Effect of PCSK9 Monoclonal Antibody Versus Placebo/Ezetimibe on Atrial Fibrillation in Patients at High Cardiovascular Risk: A Meta-Analysis of 26 Randomized Controlled Trials[J]. Cardiovasc Drugs Ther, 2022.
[33] Lopaschuk GD, Karwi QG, Tian R, et al. Cardiac Energy Metabolism in Heart Failure[J]. Circ Res, 2021, 128(10): 1487-1513. doi: 10.1161/CIRCRESAHA.121.318241
[34] Da Dalt L, Castiglioni L, Baragetti A, et al. PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction[J]. Eur Heart J, 2021, 42(32): 3078-3090. doi: 10.1093/eurheartj/ehab431
[35] Chandrakala AN, Sukul D, Selvarajan K, et al. Parthasarathy, Induction of brain natriuretic peptide and monocyte chemotactic protein-1 gene expression by oxidized low-density lipoprotein: relevance to ischemic heart failure[J]. Am J Physiol Cell Physiol, 2012, 302(1): C165-177. doi: 10.1152/ajpcell.00116.2011
[36] Dehn S, Thorp EB. Myeloid receptor CD36 is required for early phagocytosis of myocardial 768 infarcts and induction of Nr4a1-dependent mechanisms of cardiac repair[J]. FASEB J, 2018, 32(1): 254-264. doi: 10.1096/fj.201700450r
[37] Miñana G, Núñez J, Bayés-Genís A, et al. Role of PCSK9 in the course of ejection fraction change after ST-segment elevation myocardial infarction: a pilot study[J]. ESC Heart Fail, 2020, 7(1): 117-122.
[38] Bayes-Genis A, Núñez J, Zannad F, et al. The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIOSTAT-CHF Subanalysis[J]. J Am Coll Cardiol, 2017, 70(17): 2128-2136. doi: 10.1016/j.jacc.2017.08.057
[39] Liu X, Yu Z, Daitoku K, et al. Human aortic valve interstitial cells obtained from patients with aortic valve stenosis are vascular endothelial growth factor receptor 2 positive and contribute to ectopic calcification[J]. J Pharmacol Sci, 2021, 145(2): 213-221. doi: 10.1016/j.jphs.2020.12.002
[40] Tsamoulis D, Siountri I, Rallidis LS. Lipoprotein(a): Its Association with Calcific Aortic Valve Stenosis, the Emerging RNA-Related Treatments and the Hope for a New Era in "Treating" Aortic Valve Calcification[J]. J Cardiovasc Dev Dis, 2023, 10(3): 96. doi: 10.3390/jcdd10030096
[41] Perrot N, Valerio V, Moschetta D, et al. Genetic and In Vitro Inhibition of PCSK9 and Calcific Aortic Valve Stenosis[J]. JACC Basic Transl Sci, 2020, 5(7): 649-661. doi: 10.1016/j.jacbts.2020.05.004
[42] de Oliveira Sá M, Cavalcanti L, Perazzo ÁM, et al. Calcific Aortic Valve Stenosis and Atherosclerotic Calcification[J]. Curr Atheroscler Rep, 2020, 22(2): 2. doi: 10.1007/s11883-020-0821-7
[43] Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves[J]. Arterioscler Thromb Vasc Biol, 1999, 19(5): 1218-1222. doi: 10.1161/01.ATV.19.5.1218
[44] Capoulade R, Mahmut A, Tastet L, et al. Impact of plasma Lp-PLA2 activity on the progression of aortic stenosis: the PROGRESSA study[J]. JACC Cardiovasc Imaging, 2015, 8(1): 26-33. doi: 10.1016/j.jcmg.2014.09.016
[45] Leopold JA. PCSK9 and Calcific Aortic Valve Stenosis: Moving Beyond Lipids[J]. JACC Basic Transl Sci, 2020, 5(7): 662-664. doi: 10.1016/j.jacbts.2020.06.004
[46] Haas ME, Levenson AE, Sun X, et al, The Role of Proprotein Convertase 961 Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia[J]. Circulation, 2016, 134(1): 61-72. doi: 10.1161/CIRCULATIONAHA.115.020912
[47] Sundararaman SS, Döring Y, van der Vorst E. PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology[J]. Biomedicines, 2021, 9(7): 793. doi: 10.3390/biomedicines9070793
[48] Berger JM, Vaillant N, Le May C, et al. PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension[J]. Atherosclerosis, 2015, 239(1): 252-259. doi: 10.1016/j.atherosclerosis.2015.01.012
-
计量
- 文章访问数: 855
- PDF下载数: 70
- 施引文献: 0
下载: